Shots:

• Beam to receive $50M up front & is eligible to receive a target option exercise fees- milestones upon achievement of development & sales milestones along with royalties on sales of products
• The agreement will combine Beam’s gene-editing technology with Sana’s ex vivo platform to use the Cas12b system for ex vivo engineered cell therapy programs
• Sana gets a non-exclusive right to use Beam’s Cas12b system with allogeneic T cell & stem cell-derived programs & can make gene edits for Sana’s hypoimmune platform. Cas12b is a CRISPR-based nuclease with a high degree of specificity & efficiency which can be used to knock out & knock-in genes in certain cell types

  | Ref: Globe Newswire | Image: Holdereauz Studio